Lexicon Pharmaceuticals (LXRX)
(Delayed Data from NSDQ)
$1.75 USD
+0.03 (1.74%)
Updated Jun 18, 2024 04:00 PM ET
After-Market: $1.76 +0.01 (0.57%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth A Momentum F VGM
Brokerage Reports
Lexicon Pharmaceuticals, Inc. [LXRX]
Reports for Purchase
Showing records 141 - 160 ( 393 total )
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Q1 Update Key Efficacy Data from Secondary Endpoints from InTandem1 Expected This Month.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
1Q17: Early Xermelo Launch Efforts Look Promising; Additional Sota Readouts Coming Soon
Provider: H.C. Wainwright & Co., Inc.
Analyst: DEEPAK S
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
May and Full Year 2017 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of May 1
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Best Ideas List: Update
Provider: WEDBUSH SECURITIES INC.
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences: Upcoming Events for the Week of April 24
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences Upcoming Events for the Week of April 10.
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
April and Full Year 2017 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Best Ideas List: Update
Provider: WEDBUSH SECURITIES INC.
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
March and Full Year 2017 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Q4/FY16 Update; Path forward for Sotagliflozin in Type 1 Diabetes Could be Defined this Year; Reiterate OUTPERFORM and $38 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
4Q16: Focusing on Xermelo Launch and Sota Readouts in 2017
Provider: H.C. Wainwright & Co., Inc.
Analyst: DEEPAK S
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
XERMELO Approved for Carcinoid Syndrome with Impending U.S. Launch; Reiterate OUTPERFORM and Raising PT to $38 on FDA Approval
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
FDA Approves Xermelo, Launch Expected Within the Week; Raising PT to $27 From $26
Provider: H.C. Wainwright & Co., Inc.
Analyst: DEEPAK S
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences: Upcoming Events for the Week of Feb 27
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Best Ideas List: Update
Provider: WEDBUSH SECURITIES INC.
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences: Upcoming Events for the Week of Feb 13
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D